Balyasny Asset Management’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.58M | Sell |
35,851
-246,170
| -87% | -$14M | ﹤0.01% | 1673 |
|
|
2025
Q4 | $11.9M | Buy |
282,021
+99,207
| +54% | +$5.55M | 0.02% | 947 |
|
|
2025
Q3 | $10.4M | Sell |
182,814
-203,476
| -53% | -$6.73M | 0.01% | 1035 |
|
|
2025
Q2 | $9.98M | Buy |
386,290
+329,616
| +582% | +$3.7M | 0.02% | 968 |
|
|
2025
Q1 | $578K | Buy |
+56,674
| New | +$740K | ﹤0.01% | 2223 |
|
|
2024
Q4 | – | Sell |
-20,023
| Closed | -$390K | – | 3096 |
|
|
2024
Q3 | $390K | Buy |
20,023
+2,419
| +14% | +$46.1K | ﹤0.01% | 2366 |
|
|
2024
Q2 | $327K | Sell |
17,604
-2,372
| -12% | -$50K | ﹤0.01% | 2207 |
|
|
2024
Q1 | $280K | Sell |
19,976
-53,357
| -73% | -$559K | ﹤0.01% | 2287 |
|
|
2023
Q4 | $622K | Sell |
73,333
-15,578
| -18% | -$118K | ﹤0.01% | 1860 |
|
|
2023
Q3 | $794K | Buy |
88,911
+85,946
| +2,899% | +$827K | ﹤0.01% | 1618 |
|
|
2023
Q2 | $25.6K | Buy |
+2,965
| New | +$31.6K | ﹤0.01% | 2150 |
|
|
2022
Q4 | – | Sell |
-967
| Closed | -$46K | – | 3076 |
|
|
2022
Q3 | $46K | Buy |
+967
| New | +$57.5K | ﹤0.01% | 2488 |
|
|
2022
Q2 | – | Sell |
-44,588
| Closed | -$3.6M | – | 3036 |
|
|
2022
Q1 | $3.6M | Buy |
44,588
+42,556
| +2,094% | +$6.3M | 0.01% | 1090 |
|
|
2021
Q4 | $412K | Sell |
2,032
-9,536
| -82% | -$2.07M | ﹤0.01% | 1664 |
|
|
2021
Q3 | $3.12M | Buy |
+11,568
| New | +$2.78M | 0.01% | 978 |
|
|
2020
Q1 | – | Sell |
-8,952
| Closed | -$2.9M | – | 1408 |
|
|
2019
Q4 | $2.9M | Buy |
+8,952
| New | +$2.6M | 0.02% | 684 |
|
|
2019
Q3 | – | Sell |
-10,789
| Closed | -$5.76M | – | 1446 |
|
|
2019
Q2 | $5.76M | Sell |
10,789
-773
| -7% | -$388K | 0.04% | 561 |
|
|
2019
Q1 | $5.83M | Buy |
11,562
+4,909
| +74% | +$2.91M | 0.04% | 537 |
|
|
2018
Q4 | $3.28M | Buy |
6,653
+5,753
| +639% | +$3.47M | 0.02% | 589 |
|
|
2018
Q3 | $823K | Buy |
+900
| New | +$768K | ﹤0.01% | 1237 |
|
|
2018
Q1 | – | Sell |
-1,933
| Closed | -$2.49M | – | 2204 |
|
|
2017
Q4 | $1.73M | Sell |
1,933
-50,919
| -96% | -$30.1M | 0.01% | 1175 |
|
|
2017
Q3 | $19M | Buy |
52,852
+18,784
| +55% | +$5.88M | 0.07% | 334 |
|
|
2017
Q2 | $9.99M | Buy |
34,068
+4,880
| +17% | +$1.41M | 0.04% | 539 |
|
|
2017
Q1 | $10.3M | Buy |
+29,188
| New | +$6.56M | 0.05% | 483 |
|
|
2016
Q1 | – | Sell |
-1,976
| Closed | -$500K | – | 1441 |
|
|
2015
Q4 | $500K | Buy |
+1,976
| New | +$406K | ﹤0.01% | 833 |
|
|
2015
Q3 | – | Sell |
-1,071
| Closed | -$201K | – | 1307 |
|
|
2015
Q2 | $201K | Buy |
+1,071
| New | +$184K | ﹤0.01% | 1016 |
|
Other funds holding NKTR
BI
TSC
VCM
PM
AC
Balyasny Asset Management's NKTR Position: Q1 2026 in Review
Balyasny Asset Management reduced its Nektar Therapeutics (NKTR) stake by 87% in Q1 2026, selling an estimated $14M and leaving 35,851 shares worth $2.58M. The position accounts for ﹤0.01% of the portfolio, ranked #1673.
Balyasny Asset Management first reported a position in NKTR in Q2 2015 and has held it in 26 quarters since. The position peaked at $19M in Q3 2017. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.
- Balyasny Asset Management held 35,851 shares of Nektar Therapeutics worth $2.58M as of Q1 2026.
- Balyasny Asset Management sold 246,170 Nektar Therapeutics shares in Q1 2026, an estimated $14M.
- Nektar Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1673 holding.
- Balyasny Asset Management first reported a position in Nektar Therapeutics in Q2 2015 and has held it in 26 quarters since.
- Balyasny Asset Management's Nektar Therapeutics position peaked at $19M in Q3 2017.
- 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.
Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.